ArticleJCO oncology practice2022
Financial Toxicity Intervention Improves Outcomes in Patients With Hematologic Malignancy.
Article in JCO oncology practice, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- Pharmacist-led interventions in hematological malignancies: a systematic review of clinical, process and economic outcomes.Frontiers in pharmacology · 2026Pooled it
- Trial
- Financial hardship in adolescent and young adult cancer survivors and adult survivors of childhood cancers.Journal of cancer survivorship : research and practice · 2026Review
- Strategies to Overcome Inequities in the Treatment of Patients with Hematologic Malignancies.Current hematologic malignancy reports · 2026Review
- Personalized risk prediction of financial toxicity in patients with cancer: an interpretable machine learning study.JNCI cancer spectrum · 2026Article
- The LIFT UP study: feasibility of systematically identifying and addressing resource needs in those with metastatic breast cancer.Breast cancer research and treatment · 2026Article
- A Multistakeholder Qualitative Analysis of Barriers to Autologous Stem Cell Transplantation for Multiple Myeloma.Clinical lymphoma, myeloma & leukemia · 2026Article
- Assessing Social Determinants of Health in Transplantation and CAR-T Recipients: Expert Panel Recommendations from the Survivorship Special Interest Group of ASTCT.Transplantation and cellular therapy · 2025Review
- Health disparities in neurology.Nature reviews. Neurology · 2025Review
- If We Build It, Why They Do Not Come? An American College of Surgeons National Quality Improvement Collaborative to Understand Barriers to Completion of Cancer Treatment.JCO oncology practice · 2025Article
- Social Needs in Cancer Survivors: A Scoping Review and Future Directions.Current oncology reports · 2025Article
- Associations between financial toxicity, health-related quality of life, and well-being in Indonesian patients with breast cancer.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025Article
- Bringing evolutionary cancer therapy to the clinic: a systems approach.NPJ systems biology and applications · 2025Review
- A Scoping Review of Interventions to Address Financial Toxicity in Pediatric and Adult Patients and Survivors of Cancer.Cancer medicine · 2025Article
- Pediatric Transplant and Cellular Therapy Consortium RESILIENT Conference on Pediatric Chronic Graft-Versus-Host Disease Survivorship After Hematopoietic Cell Transplantation: Part IV. Patient Important Outcomes.Transplantation and cellular therapy · 2025Article
- Cross-Cultural Validation of the COmprehensive Score for Financial Toxicity (COST) Measure in an Australian Sample.Cancer medicine · 2025Article
- Interventions to Address Cancer-Related Financial Hardship: A Scoping Review and Call to Action.JCO oncology practice · 2025Article
- Financial Toxicity in Older Adults With Cancer and Their Caregivers.JCO oncology practice · 2025Review
- Medical-financial partnerships for improving financial and medical outcomes for lower-income Americans: A systematic review.Campbell systematic reviews · 2024Review
- Cancer survivor preferences on the timing and content of interventions to mitigate financial toxicity associated with cancer treatment.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
Corrections and comments
- Commented on by
Authors and funding
14 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePatients with hematologic malignancies are extremely vulnerable to financial toxicity (FT) because of the high costs of treatment and health care utilization. This pilot study identified patients at high risk because of FT and attempted to improve clinical outcomes with comprehensive intervention.
methodsAll patients who presented to the Levine Cancer Institute's Leukemia Clinic between May 26, 2019, and March 10, 2020, were screened for inclusion by standardized two question previsit survey. Patients screening positive were enrolled in the comprehensive intervention that used nurse navigators, clinical pharmacists, and community pro bono financial planners. Primary outcomes were defined as improvement in mental and physical quality of life in all patients and improvement in overall survival in the high-risk disease group.
resultsOne hundred seven patients completed comprehensive intervention. Patients experiencing FT had increased rates of noncompliance including to prescription (16.8%) and over-the-counter medications (15.9%). The intervention resulted in statistically significantly higher quality of life when measured by using Patient-Reported Outcomes Measurement Information System physical (12.5 ± 2.2
conclusionScreening and intervention on FT for patients with hematologic malignancies is associated with increased quality of life and survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.